- Home
- GTEC vs HCWB Comparison
GTEC vs HCWB Comparison
Compare GTEC & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GTEC | HCWB |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7M | 5.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | GTEC | HCWB |
|---|---|---|
| Price | $1.03 | $1.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | ★ 212.4K | 63.9K |
| Earning Date | 11-07-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.92 | N/A |
| Revenue | ★ $86,168,664.00 | $422,026.00 |
| Revenue This Year | $5.64 | $178.64 |
| Revenue Next Year | $3.93 | N/A |
| P/E Ratio | $1.13 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.92 | $1.52 |
| 52 Week High | $2.92 | $41.20 |
Technical Indicators
Market Signals| Indicator | GTEC | HCWB |
|---|---|---|
| Relative Strength Index (RSI) | 50.16 | 31.79 |
| Support Level | $0.99 | $1.52 |
| Resistance Level | $1.09 | $2.15 |
| Average True Range (ATR) | 0.07 | 0.17 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 66.00 | 33.09 |
Price Performance
Historical ComparisonAbout GTEC Greenland Technologies Holding Corporation
Greenland Technologies Holding Corp is a developer of quality solutions in the material handling industry. It is a transmission and drivetrain systems provider for material handling equipment such as forklift trucks for industrial and logistic applications. Geographically, the company has its presence in Domestic and International markets and earns majority of the revenue from Domestic Sales.
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.